RPR 200765A
Alternative Names: RPR-200765ALatest Information Update: 04 Jul 2002
At a glance
- Originator Aventis
- Class Anti-inflammatories; Antirheumatics; Imidazoles; Mesylates; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 10 Dec 1999 New profile
- 10 Dec 1999 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)